Lenalidomide-4-aminomethyl is primarily utilized in the development of novel therapeutic agents, particularly in the field of oncology. It serves as a key intermediate in the synthesis of more complex molecules designed for targeted cancer treatments. Its structure allows for modifications that enhance the efficacy and specificity of drugs aimed at inhibiting tumor growth or inducing apoptosis in cancer cells. Additionally, it is explored in immunomodulatory therapies, where it can help regulate the immune system to better recognize and attack malignant cells. Researchers also investigate its potential in combination therapies to improve the outcomes of existing cancer treatments.